Antitumor Effect of 5-Fluorouracil-Loaded Liposomes Containing n-3 Polyunsaturated Fatty Acids in Two Different Colorectal Cancer Cell Lines.


Journal

AAPS PharmSciTech
ISSN: 1530-9932
Titre abrégé: AAPS PharmSciTech
Pays: United States
ID NLM: 100960111

Informations de publication

Date de publication:
06 Jan 2021
Historique:
received: 03 08 2020
accepted: 01 12 2020
entrez: 6 1 2021
pubmed: 7 1 2021
medline: 11 3 2021
Statut: epublish

Résumé

It has been shown that long-chain n-3 polyunsaturated fatty acids (n-3 PUFAs) could act synergistically with 5-fluorouracil (5-FU) to kill cancer cells. To facilitate their simultaneous transport in the bloodstream, we synthesized, for the first time, liposomes (LIPUFU) containing 5-FU in the aqueous core and docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) at a ratio of 1:2 in the lipid bilayer. LIPUFU werestable with uniform size of 154 ± 4 nm, PDI of 0.19 ± 0.03 and zeta potential of -41 ± 2 mV. They contained 557 ± 210 μmol/l DHA, 1467 ± 362 μmol/l EPA, and 9.8 ± 1.1 μmol/l 5-FU. Control liposomes without (LIP) or with only 5-FU (LIFU) or n-3 PUFAs (LIPU) were produced in a similar way. The effects of these different liposomal formulations on the cell cycle, growth, and apoptosis were evaluated in two human colorectal cancer (CRC) cell lines differing in sensitivity to 5-FU, using fluorescence-activated cell sorting analyses. LIPUFU were more cytotoxic than LIP, LIFU, and LIPU in both LS174T (p53

Identifiants

pubmed: 33404935
doi: 10.1208/s12249-020-01897-5
pii: 10.1208/s12249-020-01897-5
pmc: PMC7788038
doi:

Substances chimiques

Antimetabolites, Antineoplastic 0
Fatty Acids, Omega-3 0
Liposomes 0
Fluorouracil U3P01618RT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

36

Références

J Cell Physiol. 2002 Jul;192(1):1-15
pubmed: 12115731
Clin Colorectal Cancer. 2015 Mar;14(1):1-10
pubmed: 25579803
Drug Deliv Transl Res. 2020 Apr;10(2):319-338
pubmed: 31701486
J Control Release. 2015 Jun 28;208:25-41
pubmed: 25617724
Ann Oncol. 2003;14 Suppl 2:ii3-5
pubmed: 12810450
J Control Release. 2011 Mar 10;150(2):212-9
pubmed: 21094191
Br J Nutr. 2013 Apr 14;109(7):1188-95
pubmed: 22874769
Biosci Biotechnol Biochem. 2002 Dec;66(12):2573-7
pubmed: 12596850
Life Sci. 2019 Jun 15;227:39-50
pubmed: 31002921
Saudi Pharm J. 2019 Jul;27(5):603-611
pubmed: 31297013
J Liposome Res. 2013 Mar;23(1):61-9
pubmed: 23363305
Eur J Pharm Sci. 2018 Mar 1;114:166-174
pubmed: 29247686
J Cell Physiol. 2018 Jul;233(7):5119-5132
pubmed: 29215746
J Mol Biol. 1965 Aug;13(1):238-52
pubmed: 5859039
Arch Pharm Res. 2003 Dec;26(12):1096-101
pubmed: 14723346
Chem Phys Lipids. 2018 May;212:73-79
pubmed: 29355517
Biomed Pharmacother. 2018 Dec;108:1259-1273
pubmed: 30372827
Anticancer Drugs. 2011 Sep;22(8):774-82
pubmed: 21799471
Ann Oncol. 2004 Jul;15(7):1025-32
pubmed: 15205195
J Phys Chem B. 2012 Jan 12;116(1):667-75
pubmed: 22148190
Nanotechnology. 2017 May 12;28(19):195602
pubmed: 28291743
Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1303-1313
pubmed: 30451549
Food Chem. 2016 Aug 15;205:196-203
pubmed: 27006231
Curr Opin Clin Nutr Metab Care. 2010 Jul;13(4):417-22
pubmed: 20453647
Lancet. 2010 Mar 20;375(9719):1030-47
pubmed: 20304247
World J Gastroenterol. 2015 May 28;21(20):6206-14
pubmed: 26034355
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
Cancer Metastasis Rev. 2018 Sep;37(2-3):545-555
pubmed: 29971573
Curr Opin Clin Nutr Metab Care. 2007 Jul;10(4):427-32
pubmed: 17563460
Biofactors. 2011 Nov-Dec;37(6):399-412
pubmed: 22038684
Food Chem. 2012 Dec 15;135(4):2761-70
pubmed: 22980870
Antioxid Redox Signal. 2012 Jun 1;16(11):1295-322
pubmed: 22117137
Cancer Chemother Pharmacol. 2014 Aug;74(2):309-22
pubmed: 24916547
Pharm Res. 2013 May;30(5):1281-90
pubmed: 23386105
Cancer Res. 1987 Apr 15;47(8):2203-6
pubmed: 3829006
Int J Cancer. 2002 Apr 1;98(4):498-504
pubmed: 11920608
Br J Cancer. 2007 Oct 8;97(7):919-26
pubmed: 17848948
Colloids Surf B Biointerfaces. 2019 Aug 1;180:9-22
pubmed: 31015105

Auteurs

Yves Marc Dupertuis (YM)

Clinical Nutrition, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland. yves.m.dupertuis@hcuge.ch.

Nathalie Boulens (N)

School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Rue Michel-Servet 1, 1211, Geneva, Switzerland.

Emmanuelle Angibaud (E)

Clinical Nutrition, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland.

Anna-Sophia Briod (AS)

Clinical Nutrition, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland.

Alexandre Viglione (A)

Clinical Nutrition, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland.

Eric Allémann (E)

School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Rue Michel-Servet 1, 1211, Geneva, Switzerland.

Florence Delie (F)

School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Rue Michel-Servet 1, 1211, Geneva, Switzerland.

Claude Pichard (C)

Clinical Nutrition, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH